← Leaderboards
Matthew Hall
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeHigh Throughput ScreeningScreeningPharmaceutical ChemistryPharmaceutical PreparationsBaseInhibitor/AntagonistBiologyLeadCollaborationsValidationResearch PersonnelTherapeutic DevelopmentExtramural ActivitiesUnited States National Institutes Of HealthPublicationsResourcesNovel TherapeuticsDrug DiscoveryCommunitiesAssay DevelopmentInformaticsCellsGenomics
Grant awards (200)
NCATS OpenData Portal: an open science resource to share drug discovery and repurposing data in real time$435,474
ZIA · FY2025 · TR · contact PI
Development of N546K and K656E Mutant FGFR Small Molecule Inhibitors$278,962
ZIA · FY2025 · TR · contact PI
Identification of small molecules capable of lowering prion protein expression$278,962
ZIA · FY2025 · TR · contact PI
Development of affinity selection mass spectrometry methods$278,962
ZIA · FY2025 · TR · contact PI
Identification of small molecules with selective cytotoxicity toward UGT3A2 KO cells$278,962
ZIA · FY2025 · TR · contact PI
Development of inhibitors of biliverdin reductase for toxic hyperbilirubinemia$278,962
ZIA · FY2025 · TR · contact PI
Identification of small molecules targeting KRAS effectors$209,221
ZIA · FY2025 · TR · contact PI
Profiling of methyltransferases$139,481
ZIA · FY2025 · TR · contact PI
Development of MENA EVH1 inhibitors to prevent cancer metastasis$139,481
ZIA · FY2025 · TR · contact PI
Screening for novel inhibitors of Glutathione Peroxidase 1 and 4$139,481
ZIA · FY2025 · TR · contact PI
Identification of small molecule inhibitors of TAP protein$69,740
ZIA · FY2025 · TR · contact PI
Development of KIAA1549-BRAF Fusion Inhibitors and Brain-Penetrant Pan-BRAF Inhibitors$69,740
ZIA · FY2025 · TR · contact PI
An OpenData Portal to share SARS-CoV-2 drug repurposing data in real time$870,948
ZIA · FY2024 · TR · contact PI
Antiviral Program for Pandemics (APP) & NCATS: Accelerating Antiviral Development$500,000
ZIA · FY2024 · TR · contact PI
Development of inhibitors of biliverdin reductase for toxic hyperbilirubinemia$327,632
ZIA · FY2024 · TR · contact PI
Identification and development of a small molecule probe for GNMT$327,632
ZIA · FY2024 · TR · contact PI
qHTS to Identify Activators and Inhibitors of Wip1$327,632
ZIA · FY2024 · TR · contact PI
qHTS to Identify Small Molecule GUS Inhibitors$327,632
ZIA · FY2024 · TR · contact PI
Development of inhibitors of RIOK3 for sickle cell anemia$327,632
ZIA · FY2024 · TR · contact PI
Screening for drugs that mobilize ATG9A from the Golgi as a potential therapy for SPG type 47, 50, 51 and 52 diseases$327,632
ZIA · FY2024 · TR · contact PI
qHTS to Identify Inhibitors of DYT1 Inclusion Formation$245,724
ZIA · FY2024 · TR · contact PI
Profiling of methyltransferases$163,816
ZIA · FY2024 · TR · contact PI
Screening for novel inhibitors of Glutathione Peroxidase 1 and 4$163,816
ZIA · FY2024 · TR · contact PI
qHTS to Identify Substrates of P-glycoprotein (P-gp) and Collateral Sensitivity agents of P-gp-expressing Cancer Cells$163,816
ZIA · FY2024 · TR · contact PI
Identification of small molecule inhibitors of TAP protein$81,908
ZIA · FY2024 · TR · contact PI
Antiviral Program for Pandemics (APP) & NCATS: Accelerating Antiviral Development$34,357,967
ZIA · FY2023 · TR · contact PI
Helping to End Addiction Long-term (HEAL): Probe/Drug Lead Production$2,687,040
ZIA · FY2023 · TR · contact PI
COVID-19: Assay Development, HTS and Drug Repurposing to identify potential therapeutics against SARS-CoV-2$2,626,150
ZIA · FY2023 · TR · contact PI
An OpenData Portal to share SARS-CoV-2 drug repurposing data in real time$2,402,379
ZIA · FY2023 · TR · contact PI
qHTS to Identify Inhibitors of NNMT1$310,142
ZIA · FY2023 · TR · contact PI
qHTS to Identify Inhibitors of DYT1 Inclusion Formation$310,142
ZIA · FY2023 · TR · contact PI
Profiling of methyltransferases$240,788
ZIA · FY2023 · TR · contact PI
Screening for novel inhibitors of Glutathione Peroxidase 1 and 4$240,788
ZIA · FY2023 · TR · contact PI
qHTS to Identify Substrates of P-glycoprotein (P-gp) and Collateral Sensitivity agents of P-gp-expressing Cancer Cells$240,788
ZIA · FY2023 · TR · contact PI
Screening for drugs that mobilize ATG9A from the Golgi as a potential therapy for SPG type 47, 50, 51 and 52 diseases$125,849
ZIA · FY2023 · TR · contact PI
qHTS to Identify Small Molecule GUS Inhibitors$125,849
ZIA · FY2023 · TR · contact PI
Development of inhibitors of biliverdin reductase for toxic hyperbilirubinemia$125,849
ZIA · FY2023 · TR · contact PI
Identification and development of a small molecule probe for GNMT$125,849
ZIA · FY2023 · TR · contact PI
Development of inhibitors of RIOK3 for sickle cell anemia$125,849
ZIA · FY2023 · TR · contact PI
qHTS to Identify Activators and Inhibitors of Wip1$125,849
ZIA · FY2023 · TR · contact PI
Antiviral Program for Pandemics (APP) & NCATS: Accelerating Antiviral Development$77,500,000
ZIA · FY2022 · TR · contact PI
COVID-19: Assay Development, HTS and Drug Repurposing to identify potential therapeutics against SARS-CoV-2$4,088,041
ZIA · FY2022 · TR · contact PI
An OpenData Portal to share SARS-CoV-2 drug repurposing data in real time$3,500,000
ZIA · FY2022 · TR · contact PI
Helping to End Addiction Long-term (HEAL): Probe/Drug Lead Production$3,002,829
ZIA · FY2022 · TR · contact PI
qHTS to Identify Inhibitors of DYT1 Inclusion Formation$425,400
ZIA · FY2022 · TR · contact PI
qHTS to Identify Inhibitors of NNMT1$425,400
ZIA · FY2022 · TR · contact PI
Development of small molecule inhibitors of ULK1$425,400
ZIA · FY2022 · TR · contact PI
Profiling of methyltransferases$259,560
ZIA · FY2022 · TR · contact PI
Identification of antagonists for GPR17 receptor$259,560
ZIA · FY2022 · TR · contact PI
Screening for novel inhibitors of Glutathione Peroxidase 1 and 4$259,560
ZIA · FY2022 · TR · contact PI
Assay Guidance Manual$250,000
ZIJ · FY2022 · TR · contact PI
Screening for drugs that mobilize ATG9A from the Golgi as a potential therapy for SPG type 47, 50, 51 and 52 diseases$146,225
ZIA · FY2022 · TR · contact PI
Identification and development of a small molecule probe for GNMT$146,225
ZIA · FY2022 · TR · contact PI
Identification of small molecules enhancers of adoptive T cell therapy efficacy$146,225
ZIA · FY2022 · TR · contact PI
qHTS to Identify Activators and Inhibitors of Wip1$146,225
ZIA · FY2022 · TR · contact PI
Development of inhibitors of biliverdin reductase for toxic hyperbilirubinemia$146,225
ZIA · FY2022 · TR · contact PI
qHTS to Identify Inhibitors of Caspase2$146,225
ZIA · FY2022 · TR · contact PI
qHTS to Identify Small Molecule GUS Inhibitors$146,225
ZIA · FY2022 · TR · contact PI
Development of inhibitors of RIOK3 for sickle cell anemia$146,224
ZIA · FY2022 · TR · contact PI
Helping to End Addiction Long-term (HEAL): Probe/Drug Lead Production$2,964,594
ZIA · FY2021 · TR · contact PI
COVID-19: Assay Development, HTS and Drug Repurposing to identify potential therapeutics against SARS-CoV-2$1,912,140
ZIA · FY2021 · TR · contact PI
COVID-19: Assay Development, HTS and Drug Repurposing to identify potential therapeutics against SARS-CoV-2$462,178
ZIA · FY2021 · TR · contact PI
qHTS to Identify Inhibitors of DYT1 Inclusion Formation$350,724
ZIA · FY2021 · TR · contact PI
Development of small molecule inhibitors of ULK1$350,724
ZIA · FY2021 · TR · contact PI
qHTS to Identify Inhibitors of NNMT1$350,724
ZIA · FY2021 · TR · contact PI
Identification of Inhibitors of the Lipid Kinase PI5P4Ka/B as Potential Anti-Cancer Agents$350,724
ZIA · FY2021 · TR · contact PI
Identification of antagonists for GPR17 receptor$201,957
ZIA · FY2021 · TR · contact PI
Screening for novel inhibitors of Glutathione Peroxidase 1 and 4$201,957
ZIA · FY2021 · TR · contact PI
Profiling of methyltransferases$201,957
ZIA · FY2021 · TR · contact PI
qHTS to Identify Small Molecule GUS Inhibitors$121,256
ZIA · FY2021 · TR · contact PI
An OpenData Portal to share SARS-CoV-2 drug repurposing data in real time$121,256
ZIA · FY2021 · TR · contact PI
qHTS to Identify Inhibitors of Caspase2$121,256
ZIA · FY2021 · TR · contact PI
qHTS to Identify Activators and Inhibitors of Wip1$121,256
ZIA · FY2021 · TR · contact PI
Assay Guidance Manual$45,000
ZIJ · FY2021 · TR · contact PI
HEAL: Probe/Drug Lead Production$2,262,666
ZIA · FY2020 · TR · contact PI
COVID-19: Assay Development, HTS and Drug Repurposing to identify potential therapeutics against SARS-CoV-2$859,275
ZIA · FY2020 · TR · contact PI
qHTS to Identify Inhibitors of DYT1 Inclusion Formation$305,662
ZIA · FY2020 · TR · contact PI
Development of small molecule inhibitors of ULK1$305,662
ZIA · FY2020 · TR · contact PI
Development of small molecule modulators of WDR5/MLL1 protein-protein binding (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$305,662
ZIA · FY2020 · TR · contact PI
Advanced development of human mutant IDH1 inhibitors (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$305,662
ZIA · FY2020 · TR · contact PI
qHTS to Identify Inhibitors of NNMT1$305,662
ZIA · FY2020 · TR · contact PI
Identification of Inhibitors of the Lipid Kinase PI5P4Ka/B as Potential Anti-Cancer Agents$305,662
ZIA · FY2020 · TR · contact PI
Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$305,662
ZIA · FY2020 · TR · contact PI
Identification of antagonists for GPR17 receptor$186,552
ZIA · FY2020 · TR · contact PI
Biologics Assay Development$186,552
ZIA · FY2020 · TR · contact PI
High-throughput screening for small molecules demonstrating toxicity against human neuroendocrine tumor cell lines$186,552
ZIA · FY2020 · TR · contact PI
qHTS to Identify Inhibitors of Mutant and Wildtype NSD2$112,360
ZIA · FY2020 · TR · contact PI
qHTS to Identify Activators and Inhibitors of Wip1$112,360
ZIA · FY2020 · TR · contact PI
Canvass: revitalizing and advancing the translation of natural products research$112,360
ZIA · FY2020 · TR · contact PI
Profiling of methyltransferases$112,360
ZIA · FY2020 · TR · contact PI
High-throughput Screening for SHH medulloblastoma$112,360
ZIA · FY2020 · TR · contact PI
qHTS to Identify Small Molecule GUS Inhibitors$112,360
ZIA · FY2020 · TR · contact PI
qHTS to Identify Inhibitors of Caspase2$112,360
ZIA · FY2020 · TR · contact PI
Screening for novel inhibitors of Glutathione Peroxidase 1 and 4$112,360
ZIA · FY2020 · TR · contact PI
HEAL: Probe/Drug Lead Production$3,197,055
ZIA · FY2019 · TR · contact PI
Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$250,290
ZIA · FY2019 · TR · contact PI
qHTS to Identify Inhibitors of DYT1 Inclusion Formation$250,290
ZIA · FY2019 · TR · contact PI
qHTS to Identify Inhibitors of NNMT1$250,290
ZIA · FY2019 · TR · contact PI
Development of small molecule modulators of WDR5/MLL1 protein-protein binding (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$250,290
ZIA · FY2019 · TR · contact PI
Development of small molecule inhibitors of ULK1$250,290
ZIA · FY2019 · TR · contact PI
NPC/MIPE Toxicity Screen of IDH1 Inhibitors against Cholangiocarcinoma Cell Lines$250,290
ZIA · FY2019 · TR · contact PI
Advanced development of human mutant IDH1 inhibitors (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$250,290
ZIA · FY2019 · TR · contact PI
qHTS for inhibitors of the NTHi Toxin VapC-1$132,650
ZIA · FY2019 · TR · contact PI
qHTS to Identify Substrates of P-glycoprotein (P-gp) and Collateral Sensitivity agents of P-gp-expressing Cancer Cells$132,650
ZIA · FY2019 · TR · contact PI
Synthesis of non-brain-permeant inhibitor of LZK$132,650
ZIA · FY2019 · TR · contact PI
qHTS to Identify Differentiators of Brown Adipocytes$132,650
ZIA · FY2019 · TR · contact PI
Biologics Assay Development$132,650
ZIA · FY2019 · TR · contact PI
Identification of antagonists for GPR17 receptor$132,650
ZIA · FY2019 · TR · contact PI
High-throughput screening for small molecules demonstrating toxicity against human neuroendocrine tumor cell lines$132,650
ZIA · FY2019 · TR · contact PI
Identification of small molecule inhibitors of the capsule synthesis of gram-negative bacteria$132,650
ZIA · FY2019 · TR · contact PI
qHTS to Identify Small Molecule GUS Inhibitors$47,590
ZIA · FY2019 · TR · contact PI
Canvass: revitalizing and advancing the translation of natural products research$47,590
ZIA · FY2019 · TR · contact PI
Identification of small molecule enhancers of CAR-T cell killing activity$47,590
ZIA · FY2019 · TR · contact PI
qHTS to Identify Inhibitors of Caspase2$47,590
ZIA · FY2019 · TR · contact PI
Identification of brain-permeant small molecule modulators of GAL1R receptor$47,590
ZIA · FY2019 · TR · contact PI
qHTS to Identify Inhibitors of Mutant and Wildtype NSD2$47,590
ZIA · FY2019 · TR · contact PI
High-throughput screening to identify small molecule inhibitors of deoxyhypusine synthase and deoxyhypusine hydroxylase$47,590
ZIA · FY2019 · TR · contact PI
qHTS to Identify Activators and Inhibitors of Wip1$47,590
ZIA · FY2019 · TR · contact PI
HEAL: Probe/Drug Lead Production$736,083
ZIA · FY2018 · TR · contact PI
qHTS to Identify Inhibitors of NNMT1$245,080
ZIA · FY2018 · TR · contact PI
Development of small molecule inhibitors of ULK1$245,080
ZIA · FY2018 · TR · contact PI
Development of small molecule modulators of WDR5/MLL1 protein-protein binding (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$245,080
ZIA · FY2018 · TR · contact PI
Advanced development of human mutant IDH1 inhibitors (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$245,080
ZIA · FY2018 · TR · contact PI
NPC/MIPE Toxicity Screen of IDH1 Inhibitors against Cholangiocarcinoma Cell Lines$245,080
ZIA · FY2018 · TR · contact PI
qHTS to Identify Inhibitors of DYT1 Inclusion Formation$245,080
ZIA · FY2018 · TR · contact PI
qHTS to Identify Activators and Inhibitors of Fumarate Hydratase$127,680
ZIA · FY2018 · TR · contact PI
High-throughput screening for inhibitors of metabolic checkpoints on the G2/mitosis transition$127,680
ZIA · FY2018 · TR · contact PI
qHTS for inhibitors of the NTHi Toxin VapC-1$127,680
ZIA · FY2018 · TR · contact PI
Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$127,680
ZIA · FY2018 · TR · contact PI
qHTS to Identify Inhibitors of the Arf GTPase-activating Protein ASAP1$127,680
ZIA · FY2018 · TR · contact PI
qHTS to Identify Substrates of P-glycoprotein (P-gp) and Collateral Sensitivity agents of P-gp-expressing Cancer Cells$127,680
ZIA · FY2018 · TR · contact PI
Identification of Inhibitors of Plasmodium falciparum hexokinase (PfHK)$127,680
ZIA · FY2018 · TR · contact PI
Identification of antagonists for GPR17 receptor$127,680
ZIA · FY2018 · TR · contact PI
Biologics Assay Development$127,680
ZIA · FY2018 · TR · contact PI
Identification of small molecule inhibitors of the capsule synthesis of gram-negative bacteria$127,680
ZIA · FY2018 · TR · contact PI
Synthesis of non-brain-permeant inhibitor of LZK$127,680
ZIA · FY2018 · TR · contact PI
qHTS to Identify Agonists of Fibroblast Growth Factor Receptor 1 (FGFR1)$127,680
ZIA · FY2018 · TR · contact PI
Identification of inhibitors of Zika Protease (NS2B-NS3)$127,680
ZIA · FY2018 · TR · contact PI
High-throughput screening for small molecules demonstrating toxicity against human neuroendocrine tumor cell lines$127,680
ZIA · FY2018 · TR · contact PI
qHTS to Identify Differentiators of Brown Adipocytes$127,680
ZIA · FY2018 · TR · contact PI
High-throughput screening to identify small molecule inhibitors of deoxyhypusine synthase and deoxyhypusine hydroxylase$40,790
ZIA · FY2018 · TR · contact PI
Identification of brain-permeant small molecule modulators of GAL1R receptor$40,790
ZIA · FY2018 · TR · contact PI
Identification of small molecule enhancers of CAR-T cell killing activity$40,790
ZIA · FY2018 · TR · contact PI
Canvass: revitalizing and advancing the translation of natural products research$40,790
ZIA · FY2018 · TR · contact PI
Advanced development of human KDM5 inhibitors (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$40,790
ZIA · FY2018 · TR · contact PI
qHTS to identify toxic agents in genetically engineered mouse model (GEMM) lines$40,790
ZIA · FY2018 · TR · contact PI
qHTS to Identify Inhibitors of Mutant and Wildtype NSD2$40,790
ZIA · FY2018 · TR · contact PI
qHTS to Identify Activators and Inhibitors of Wip1$40,790
ZIA · FY2018 · TR · contact PI
qHTS to Identify Small Molecule GUS Inhibitors$40,790
ZIA · FY2018 · TR · contact PI
qHTS to Identify Inhibitors of Caspase2$40,790
ZIA · FY2018 · TR · contact PI
Identification of Inhibitors of Phosphoglycerate Dehydrogenase (PHGDH)$251,630
ZIA · FY2017 · TR · contact PI
BRD4 Inhibitors as Potential Therapeutics for Oncology$251,630
ZIA · FY2017 · TR · contact PI
PET radiolabeling of mutant IDH1 inhibitors$251,630
ZIA · FY2017 · TR · contact PI
Advanced development of human mutant IDH1 inhibitors (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$251,630
ZIA · FY2017 · TR · contact PI
Development of small molecule modulators of WDR5/MLL1 protein-protein binding (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$251,630
ZIA · FY2017 · TR · contact PI
NPC/MIPE Toxicity Screen of IDH1 Inhibitors against Cholangiocarcinoma Cell Lines$135,676
ZIA · FY2017 · TR · contact PI
qHTS to Identify Compounds against Merkel Cell Carcinoma (MCC)$135,676
ZIA · FY2017 · TR · contact PI
Identification of inhibitors of Zika Protease (NS2B-NS3)$135,676
ZIA · FY2017 · TR · contact PI
Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$135,676
ZIA · FY2017 · TR · contact PI
qHTS to Identify Inhibitors of the Arf GTPase-activating Protein ASAP1$135,676
ZIA · FY2017 · TR · contact PI
qHTS to Identify Substrates of P-glycoprotein (P-gp) and Collateral Sensitivity agents of P-gp-expressing Cancer Cells$135,676
ZIA · FY2017 · TR · contact PI
qHTS to Identify Inhibitors of NNMT1$44,666
ZIA · FY2017 · TR · contact PI
Development of potent and specific in vivo probe for human fructose transporter GLUT5$44,666
ZIA · FY2017 · TR · contact PI
qHTS to identify toxic agents in genetically engineered mouse model (GEMM) lines$44,666
ZIA · FY2017 · TR · contact PI
qHTS to Identify Inhibitors of Mutant and Wildtype NSD2$44,666
ZIA · FY2017 · TR · contact PI
Biologics Assay Development$44,666
ZIA · FY2017 · TR · contact PI
Canvass: revitalizing and advancing the translation of natural products research$44,666
ZIA · FY2017 · TR · contact PI
Advanced development of human KDM5 inhibitors (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$44,666
ZIA · FY2017 · TR · contact PI
qHTS to Identify Differentiators of Brown Adipocytes$44,666
ZIA · FY2017 · TR · contact PI
Identification of Inhibitors of Plasmodium falciparum hexokinase (PfHK)$44,666
ZIA · FY2017 · TR · contact PI
qHTS for inhibitors of the NTHi Toxin VapC-1$44,666
ZIA · FY2017 · TR · contact PI
qHTS to Identify Molecular Activators and Inhibitors of Tyrosinase$44,666
ZIA · FY2017 · TR · contact PI
qHTS to Identify Activators and Inhibitors of Wip1$44,666
ZIA · FY2017 · TR · contact PI
qHTS to Identify Inhibitors of DYT1 Inclusion Formation$44,666
ZIA · FY2017 · TR · contact PI
WDR5$226,982
ZIA · FY2016 · TR · contact PI
qHTS to Identify Inhibitors of the Arf GTPase-activating Protein ASAP1$121,984
ZIA · FY2016 · TR · contact PI
qHTS to identify toxic agents in genetically engineered mouse model (GEMM) lines$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Activators of hTERT$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Antagonists of GPR31$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Agonists of Orphan Receptor GPR101$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Inhibitors of Fumarate Hydratase$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Inhibitors of Mutant and Wildtype NSD2$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Inhibitors of NNMT1$37,474
ZIA · FY2016 · TR · contact PI
Identification of Inhibitors and Activators of FOXP3 to Modulate Differentiation of T Suppressor Cells$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Inducers of Oligodendrocyte-precursor cell (OPC) Remyelination$37,474
ZIA · FY2016 · TR · contact PI
Identification of Inhibitors and Activators of Clp Proteases$37,474
ZIA · FY2016 · TR · contact PI
NPC/MIPE Toxicity Screen of IDH1 Inhibitors against Cholangiocarcinoma Cell Lines$37,474
ZIA · FY2016 · TR · contact PI
Identification of Inhibitors of Plasmodium falciparum hexokinase (PfHK)$37,474
ZIA · FY2016 · TR · contact PI
Identification of Inhibitors of Yes1 Kinase Activity and Determination of Yes1 Polypharmacology of Kinase Inhibitors$37,474
ZIA · FY2016 · TR · contact PI
qHTS for inhibitors of the NTHi Toxin VapC-1$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Molecular Activators and Inhibitors of Tyrosinase$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Activators and Inhibitors of Wip1$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Differentiators of Brown Adipocytes$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Activators of E47$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Inhibitors of ClpP$37,474
ZIA · FY2016 · TR · contact PI
qHTS to Identify Substrates of P-glycoprotein (P-gp) and Collateral Sensitivity agents of P-gp-expressing Cancer Cells$57,000
ZIA · FY2015 · TR · contact PI
qHTS to Identify Inhibitors of the Arf GTPase-activating Protein ASAP1$57,000
ZIA · FY2015 · TR · contact PI
Identification of Toxic Agents against Leishmania mexicana$19,000
ZIA · FY2015 · TR · contact PI
qHTS to Identify Inhibitors of the Trypanosoma brucei Hexose Transporter 1 (TbHT1)$19,000
ZIA · FY2015 · TR · contact PI
Identification of Inhibitors and Activators of FOXP3 to Modulate Differentiation of T Suppressor Cells$19,000
ZIA · FY2015 · TR · contact PI